Enoblituzumab is a humanized IgG1 κmab monoclonal antibody that recognizes human B7-H3 protein and can be used to study solid tumors such as non-small cell lung cancer (NSCLC).

Enoblituzumab interacts with B7-H3, resulting in potent antibody-dependent cellular cytotoxicity (ADCC) across a broad range of cancer cells[2]. It effectively mediates ADCC against A498 cells at concentrations ranging from 0.01 ng/mL to 10 mg/mL using cynomolgus monkey peripheral blood mononuclear cells (PBMCs)[3].

In mice (mCD16-/-hCD16A+) with murine CD16 gene knocked out and transgenic for human CD16A-158F, enoblituzumab (5 mg/kg; i.v.; single dose) exhibits an estimated half-life of 249 hours with a Cmax of 43 mg/mL[3].
Exhibiting potent antitumor activity in xenograft mice models of renal cell and bladder carcinoma expressing B7-H3, enoblituzumab (0.1-10 mg/kg; i.v.; once weekly; 5 weeks) shows this effect[3].